Functional vision restored in Leber's congenital amaurosis patients

Article

Gene therapy has resulted in functional vision for patients with Leber's congenital amaurosis (LCA), said Albert Maguire, MD, of the University of Pennsylvania, Bryn Mawr. That research is the result of a 13-year effort by Dr. Maguire and colleagues.

Gene therapy has resulted in functional vision for patients withLeber's congenital amaurosis (LCA), said Albert Maguire, MD, ofthe University of Pennsylvania, Bryn Mawr. That research is theresult of a 13-year effort by Dr. Maguire and colleagues.

Their previous well-known work involved successfully delivering aviral vector into dogs with LCA. The dogs lacked the RPE65 geneneeded to process vitamin A. Successful restoration of vision indogs treated with a subretinal injection of the viral vectorcontaining RPE65 was the basis for the clinical work inhumans.

In a phase I clinical safety trial, three groups of threepatients each were treated in one eye only with a subretinalinjection of either a low-, medium-, or high-dose of the RPE65vector, Dr. Maguire said. The treated eye then was evaluated fora response and compared with the untreated fellow eye.

"All patients in the low-dose cohort had substantial visualacuity improvement," he said. Visual field testing indicated thatthe visual fields were larger in the treated eyes compared withthe control eyes. In addition, the patients' pupils alsoresponded to light despite a flat electroretinogram.

Dr. Maguire emphasized that the vision was indeed functional, andhe demonstrated patients navigating an obstacle course "quicklyand confidently," which previously had been an impossibletask.

Results of the study were published in April 2008 in the NewEngland Journal of Medicine.

Newsletter

Stay at the forefront of cutting-edge science with CGT—your direct line to expert insights, breakthrough data, and real-time coverage of the latest advancements in cell and gene therapy.

Recent Videos
Derek Jackson, BS, MA, the vice president of cell & gene therapy product development at Pacira, and Kilian Guse, PhD, the vice president of genetic medicine platforms at Pacira
Derek Jackson, BS, MA, the vice president of cell & gene therapy product development at Pacira
Jeffrey Chamberlain, PhD
Tami John, MD
Tami John, MD
Tami John, MD
Matthew Ku, MBBS, FRACP, RACP, FRCPA/RCPA, PhD, an associate professor and the lymphoma stream lead at St Vincent’s Hospital
Saurabh Dahiya, MD, FACP, an associate professor of medicine at Stanford University School of Medicine; as well as clinical director of Cancer Cell Therapy in the Division of Blood and Marrow Transplantation and Cell Therapy at Stanford Medicine
Shahzad Raza, MD, a hematologist/oncologist at the Cleveland Clinic
Manali Kamdar, MD, the associate professor of medicine–hematology and clinical director of lymphoma services at the University of Colorado
Related Content
© 2025 MJH Life Sciences

All rights reserved.